MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

MDS Virtual Congress 2021

September 17-22, 2021. Virtual Congress. www.mdscongress.org

View by Title View Categories
Jump to:  View All • a b c d [e] f g h i j k l m n o p q r s t u v w x y z
  • Early Adapter: Study Protocol for the Multi-Center Post-Market Study of Adaptive Deep Brain Stimulation (aDBS) in Japan

    G. Oyama, A. Nakajima, H. Kamo, M. Nuermaimaiti, A. Bovet, J. Eubanks, H. Iwamuro, A. Umemura, N. Hattori, Y. Shimo (Tokyo, Japan)

  • Early detection of change in motor and cognitive symptoms in a longitudinal Progressive Supranuclear Palsy cohort – the OxQUIP study.

    M. Pereira, C. Antoniades (Oxford, United Kingdom)

  • Early Observations of Using a Chronically Implanted INS that can Sense Local Field Potentials in Movement Disorder Patients

    T. Theys, M. Case, A. van Hoylandt, A. Singer, K. Bhatia (Leuven, Belgium)

  • Early versus later levodopa and onset of motor fluctuations in PD: Observations from the Parkinson’s Outcomes Project

    S. Chiu, A. Ramirez-Zamora, B. Patel, S. Wu, H. Gao, O. Nguyen, I. Malaty (Gainesville, USA)

  • Early-onset Dementia with Lewy Bodies and Parkinson’s Disease Dementia: A Population-based Study (2010-2015).

    E. Camerucci, C. Stang, M. Hajeb, P. Turcano, A. Mullan, D. Jones, J. Graff-Radford, O. Ross, J. Bower, B. Boeve, R. Savica (Rochester, USA)

  • Early-onset vs. Late-onset Parkinson’s disease

    H. Slimène, N. Farhat, S. Sakka, O. Hdiji, M. Dammak, C. Mhiri (Sousse, Tunisia)

  • East Asian Parkinson’s Disease Genomics Consortium – An introduction

    K. Mok (London, United Kingdom)

  • EATING HABITS AND NUTRITIONAL STATUS OF PATIENTS WITH HEREDITARY ATAXIAS IN A NORTHEAST BRAZILIAN POPULATION

    CGM. Carvalho, SSO. Scott, DM. Rangel, DMS. Soares, PBN. Neto (Fortaleza, Brazil)

  • ECHOCARDIOGRAPHY FINDINGS IN PARKINSON’S DISEASE

    R. Erol Yildiz, G. Yuksel, H. Tireli (Istanbul, Turkey)

  • Effect of bilateral pallidal stimulation on quality of life of pediatric patients with dyskinetic cerebral palsy (STIM-CP): A prospective single-arm multicenter study with a subsequent randomized double-blind crossover phase

    A. Koy, A. Kühn, J. Huebl, G-H. Schneider, A. van Riesen, M. Eckenweiler, C. Rensing-Zimmermann, V. Coenen, J. Krauss, A. Saryyeva, H. Hartmann, M. Haeussler, J. Volkmann, C. Matthies, A. Horn, A. Schnitzler, J. Vesper, A. Gharabaghi, D. Weiss, A. Bevot, W. Marks, A. Pomykal, E. Monbaliu, G. Borck, J. Mueller, R. Prinz-Langenohl, T. Dembek, V. Visser-Vandewalle, J. Wirths, P. Schiller, M. Hellmich, L. Timmermann (Cologne, Germany)

  • Effect of COVID-19 stressors on mental health and quality of life in Parkinson’s disease

    L. Dommershuijsen, A. Heide, E. Berg, J. Labrecque, M K. Ikram, M A. Ikram, B. Bloem, R. Helmich, S. Darweesh (Nijmegen, Netherlands)

  • Effect of DBS on Swallowing function in Parkinson’s disease as assessed by Video fluoroscopy

    K. Henry, R. Singh, N. Zhang, K. Mcnett, M. Lyons, S. Mehta (Scottsdale, USA)

  • Effect of deep brain stimulation on pallidal local field potential activity in a patient with Holmes tremor

    L. Hammer, R. Kochanski, M. Volz, N. Galifianakis, S. Little, P. Starr (San Francisco, USA)

  • Effect of deep brain stimulation on quality of life of patients with Parkinson’s Disease

    V. Junior, I. Andrade, L. Castanheira, B. Orleans, F. da Silva, L. Magalhães (Salvador, Brazil)

  • Effect of dopaminergic treatment on digital sensor features in Phase II PASADENA Part 1 in early Parkinson’s disease

    B. van Lier, J. Anzures Cabrera, E. Volkova-Volkmar, L. Essioux, H. Svoboda, W. Zago, G. Pagano, R. Postuma, M. Lindemann, K. Taylor, F. Lipsmeier (Basel, Switzerland)

  • Effect of H. pylori Infection on L-DOPA Pharmacokinetics in Patients with Parkinson’s disease.

    S. Oda, Y. Saitoh, J. Takei, S. Watanabe, Y. Mukai, Y. Takahashi (Kodaira, Japan)

  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson’s Disease

    M. Beke, P. Mackie, C. Rusch, E. Klann, A. Gurrala, S. Chua, E. Ince, L. Almeida, A. Ramirez-Zamora (Gainesville, USA)

  • Effect of oxytocin on response inhibition in Parkinson´s disease: a pilot study

    F. Carbone, P. Ellmerer, S. Spielberger, M. Peball, V. Sidoroff, M. Ritter, K. Seppi, W. Poewe, A. Djamshidian (Innsbruck, Austria)

  • Effect of physical exercises on gait speed in patients with Parkinson’s disease

    D. Bueno, L. Oliveira, L. Ota, P. Polidoro, G. da Costa (Dracena, Brazil)

  • Effect of probiotics on MDS UPDRS in Parkinson disease at 12 weeks: A Randomized double-blind placebo-controlled trial

    G. George, T. Iype (Thiruvananthapuram, India)

  • Effect of simultaneous mGlu2 positive allosteric modulation and orthosteric stimulation combined with 5-HT2A antagonism on psychosis-like behaviours, dyskinesia and parkinsonism in the MPTP-lesioned marmoset

    S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

  • Effect of the GlyT1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset

    I. Frouni, SG. Nuara, D. Bédard, A. Hamadjida, JC. Gourdon, P. Huot (Montreal, Canada)

  • Effect of the mGlu2/3 orthosteric agonist LY-404,039 on abnormal involuntary movements and parkinsonism in the 6-OHDA-lesioned rat

    W. Kang, I. Frouni, C. Kwan, L. Desbiens, D. Bédard, A. Hamadjida, P. Huot (Montreal, Canada)

  • EFFECT OF TRANSCRANIAL DIRECT CURRENT STIMULATION (tDCS) ON LOCOMOTOR FUNCTION IN PATIENTS WITH PARKINSON’S DISEASE

    M. Shah, B. Bajaj, I. Ali (New Delhi, India)

  • Effect of Venglustat by GBA Mutation Severity in Patients With Parkinson’s Disease

    J. Peterschmitt, N. Giladi, R. Alcalay, G. Cutter, G. Höglinger, A. Schapira, C. Scherzer, T. Simuni, T. Gurevich, T. Gasser, C. Pacchetti, K. Marek, P. Minini, S. Sardi (Cambridge, USA)

  • Effectiveness of a novel cognitive rehabilitation program based on mindfulness and reminiscence in patients with Parkinson’s Disease and Mild Cognitive Impairment: a pilot study

    M. Reitano, M. Dini, F. Ruggiero, S. Tagini, F. Solca, B. Poletti, A. Priori, R. Ferrucci (Milan, Italy)

  • Effectiveness of an intensive and structured therapy (LSVT-BIG) in comparison to conventional therapy for people with Parkinson’s disease in Singapore.

    D. Maniam, JQ. Yong, V. Tan (Singapore, Singapore)

  • EFFECTIVENESS OF NEUROFUNCTIONAL PHYSICAL THERAPY ON THE QUALITY OF SLEEP OF INDIVIDUALS WITH PARKINSON’S DISEASE: A SERIES OF CASES

    R. Souza, S. Smaili, I. Almeida, M. Terra, N. Barboza, ME. Bueno, A. Mesas (Londrina, Brazil)

  • Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of entacapone: findings from the real-world OPTIPARK study

    W. Jost, H. Reichmann, A. Lees, D. Marinho, D. Magalhães, J. Rocha, P. Soares-da-Silva (Wolfach, Germany)

  • Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of monoamine-oxidase-B inhibitors (MAO-B) and dopamine agonists (DA): findings from the real-world OPTIPARK study

    H. Reichmann, T. Warnecke, A. Lees, D. Martins, D. Magalhães, J. Rocha, P. Soares-da-Silva (Dresden, Germany)

  • Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of safinamide: findings from the real-world OPTIPARK study

    N. Pavese, A. Lees, H. Reichmann, D. Martins, D. Magalhães, J. Rocha, P. Soares-da-Silva (Newcastle Upon Tyne, United Kingdom)

  • Effectiveness of the use of home-based action observation training in subjects with Parkinson’s disease

    M. Putzolu, C. Cosentino, S. Mezzarobba, G. Bonassi, A. Botta, G. Lagravinese, C. Ponte, L. Avanzino, E. Pelosin (Genoa, Italy)

  • Effects of Angiotensin Type 1 Receptor Antagonists on Parkinson’s Disease Progression: an exploratory study in the PPMI database

    L. Udovin, M. Otero-Losada, S. Bordet, G. Chevalier, C. Quarracino, F. Capani, S. Perez-Lloret (Buenos Aires, Argentina)

  • Effects of dopaminergic medication on reinforcement learning in Parkinson’s disease depend on depressive symptoms

    J. Tichelaar, C. Sayali, R. Helmich, R. Cools (Nijmegen, Netherlands)

  • Effects of fine particulate matter and cigarette smoking on MPTP-induced dopaminergic neuronal cell death: Implication for Parkinson’s disease

    YJ. Jung, H. Choi, E. Oh (Seoul, Republic of Korea)

  • Effects of freezing gait and medication on postural control during prolonged standing in individuals with Parkinson’s disease

    L. Cupertino, CR. de Souza, CN. de Oliveira, R. Treza, SM. Hondo, E. Los Angeles, C. Bernardo, MJ. Carvalho, DB. Coelho (Sp, Brazil)

  • Effects of Gandouling Tablets on the Muscle tone and stiffness of patients with Wilson’s disease: a randomized, double-blind, placebo-controlled study

    W. Hao (Hefei, China)

  • Effects of levodopa dose on temporal dynamics of cortical activity and postural control in people with Parkinson’s disease

    FAB. Barbieri, FAS. Araújo-Silva, FBS. Santinelli, LFI. Imaizumi, APS. Silveira, LHV. Palucci Vieira, LA. Alcock (Bauru, Brazil)

  • Effects of levodopa on cognitive functions in Parkinson’s disease

    S. Ismailova, S. Prokopenko (Krasnoyarsk, Russian Federation)

  • Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms including Sleep: Results from a Meta-Analysis with 24-month follow-up

    K. Chaudhuri, A. Antonini, R. Pahwa, P. Odin, N. Titova, S. Thakkar, S. Snedecor, S. Hegde, A. Alobaidi, Y. Jalundhwala, J. Parra, C. Zadikoff, L. Bergmann, D. Standaert (London, United Kingdom)

  • Effects of low frequency repetitive transcranial stimulation over right dorsolateral prefrontal region on clinical symptoms and sleep structure of Parkinson’s disease Abstract

    WU. Jing, C. Jing, Z. Sheng, LIU. Feng (Suzhou, China)

  • Effects of Once-Daily Opicapone 50 mg on the Pharmacokinetics of Levodopa Administered as Carbidopa/Levodopa Extended-Release Capsules: An Open-Label Phase 1 Study

    G. Loewen, A. Vijan, K. Olson, T. O’Reilly, G. Liang, O. Klepitskaya (San Diego, USA)

  • Effects of Opicapone on Sleep in Patients with Parkinson’s Disease and Motor Fluctuations

    R. Hauser, A. Videnovic, P. Soares-da-Silva, G. Liang, K. Olson, E. Jen, JF. Rocha, O. Klepitskaya (Miami, USA)

  • Effects of Parkinson’s disease on blur-driven and disparity-driven vergence eye movements

    P. Gupta, S. Beylergil, J. Murray, A. Shaikh, F. Ghasia (Cleveland, USA)

  • Effects of psychiatric tests on disease severity and nonmotor symptoms in early onset Parkinson’s Disease

    A. Tuncer, G. Yuksel, B. Hasırcı (İstanbul, Turkey)

  • Effects of safinamide adjunct therapy on non-motor symptoms in patients with Parkinson’s disease: a post-hoc analysis of the Japanese Phase 2/3 study

    N. Hattori, Y. Tsuboi, Y. Kogo, M. Koebisu, T. Ishida, I. Suzuki, M. Nomoto (Tokyo, Japan)

  • Effects of white matter hyperintensities, neuropsychiatric symptoms, and cognition on activities of daily living: Differences between Dementia with Lewy Bodies and Alzheimer’s disease

    S. Mirza, U. Saeed, J. Ramirez, N. Herrmann, S. Black, M. Masellis (Toronto, Canada)

  • Efficacy and safety of Botulinum toxin (BoNT) in lingual dystonia

    D. Nene, S. Cresswell (Vancouver, Canada)

  • Efficacy and safety of incobotulinumtoxinA for upper- or combined upper- and lower-limb spasticity in children/adolescents with cerebral palsy: the XARA study

    E. Dabrowski, H. Chambers, D. Gaebler-Spira, M. Banach, P. Kaňovský, A. Hanschmann, M. Althaus, T. Geister, F. Heinen (Royal Oak, USA)

  • Efficacy and safety of Levodopa-Carbidopa Intestinal Gel in the treatment of Parkinson’s Disease

    E. Londero, A P. Dos Santos, R. Braga, R. de Barros, L. Dos Reis, G. Freire (Salvador, Brazil)

  • Efficacy of a 6-week brisk walking program in improving non-motor symptoms in people with Parkinson disease – a randomized controlled trial

    M. Mak, ISK. Wong-Yu, LJ. Ren (Hong Kong Sar, China)

  • Efficacy of Incobotulinumtoxin/A Treatment for Children/Adolescents with Sialorrhea associated with Neurological Disorders

    S. Berweck, H. Kim, M. Banach, A. Hanschmann, M. Althaus, M. Bonikowski (Vogtareuth, Germany)

  • Efficacy of opicapone according to different levodopa daily intakes in Parkinson’s disease patients with motor fluctuations

    G. Ebersbach, W. Poewe, J. Ferreira, D. Magalhaes, J. Rocha, P. Soares-da-Silva (Beelitz-Heilstätten, Germany)

  • Efficacy of opicapone according to levodopa’s duration of use in Parkinson’s disease patients with motor fluctuations

    A. Antonini, G. Ebersbach, O. Rascol, D. Magalhaes, J. Rocha, P. Soares-da-Silva (Padova, Italy)

  • Efficacy of the ankle bracelet-laser to improve gait in Parkinson disease (PD).

    P. Ruthiraphong, C. Ratanasutiranont, K. Srisilpa (Bangkok, Thailand)

  • EIF4G1 gene variants in a family affected by Parkinson´s disease

    C. Borrue (San Sebastián Reyes, Spain)

  • ELECTRICAL ACTIVITY OF THE MASTICATORY MUSCLES OF PARKINSONIANS INFLUENCED BY THE USE OF REMOVABLE DENTAL PROSTHESIS

    J. Oliveira, A. Sobral, T. Silva, M. Coriolano, C. Lins (Recife, Brazil)

  • Electroconvulsive therapy for refractory psychiatric symptoms in GBA-related Parkinson disease patient

    JY. Yun, EH. Lee (Seoul, Republic of Korea)

  • Electrophysiological testing aids the diagnosis of tremor versus myoclonus in clinically challenging patients

    C. Everlo, JW. Elting, M. Tijssen, M. V.D. Stouwe (Groningen, Netherlands)

  • Elucidating Factors Influencing Machine Learning Algorithm Prediction in Spasticity Assessment: A Prospective Cross Sectional Observational Study

    N. Mohamad Hashim, JY. Yee, NA. Othman, K. Johar, CY. Low, FA. Hanapiah, NA. Che Zakaria (Sungai Buloh, Malaysia)

  • Elucidating multimodal endophenotypes of APOE-ε4 in α-synucleinopathies

    U. Saeed, SS. Mirza, SE. Black, M. Masellis (Toronto, Canada)

  • Emergence of new symptoms in experiences of daily living in early Parkinson’s disease

    J. Cedarbaum, M. Tosin, T. Simuni, G. Stebbins (Woodbridge, USA)

  • Emerging parkinsonism in the PREDICT-PD cohort after 6-years of follow-up

    C. Simonet, A. Gill, J. Bestwick, A. Lees, G. Giovannoni, A. Schrag, A. Noyce (London, United Kingdom)

  • Emotional and cognitive information processing in obstacle negotiation in patient with Parkinson’s disease and freezing

    S. Mezzarobba, M. Grassi, E. Pelosin, P. Manganotti, P. Bernardis (Genova, Italy)

  • Emotional processing and response times in Parkinson’s disease

    A. Botta, G. Lagravinese, E. Pelosin, G. Bonassi, M. Putzolu, C. Cosentino, C. Ponte, S. Mezzarobba, L. Avanzino (Genova, Italy)

  • Emotional stress exacerbates parkinsonian resting tremor

    R. Blakemore, M. Pascoe, D. Myall, M. Macaskill, T. Anderson (Dunedin, New Zealand)

  • Emotional, logistical and ethical aspects of voluntarily stopping eating and drinking in patients with movement disorders

    J. Shurer, M. Buchbinder, N. Browner (Chapel Hill, USA)

  • Encoding, consolidation, and retrieval performance in memory tasks of MCI and n-MCI patients with Parkinson’s Disease.

    J. Heredia, P. Berrones-Silva, X. Ortiz-Jiménez, I. Estrada-Bellman (Monterrey, Mexico)

  • Endoscopic Characteristics of Dysphagia in Multiple System Atrophy compared to Parkinson’s Disease

    A. Vogel, I. Claus, S. Ahring, D. Gruber, A. Haghikia, U. Frank, R. Dziewas, G. Ebersbach, T. Warnecke, F. Gandor (Beelitz-Heilstätten, Germany)

  • Engage-PD: a Physical Activity Coaching Program via Telehealth for people with Parkinson’s Disease – Preliminary results a year after inception.

    C. Macpherson, M. King, H. Shih, J. Rieger, J. Fineman, J. Reid, A. Pacheco, H. Shah, R. Alcalay, L. Quinn (New York City, USA)

  • Enhanced arm swing improves Parkinson gait associated with EEG power modulations resembling those in healthy gait.

    J. Weersink, N. Maurits, B. de Jong (Groningen, Netherlands)

  • Enhancement of visuospatial function underlies motor improvement following art therapy in PD

    A. Cucca, A. Di Rocco, I. Acosta, M. Berberian, H. Bertish, M. Inglese, D. Mania, A. Quartarone, J. Rizzo, E. Tatti, F. Carrara, A. Feigin, M. Ghilardi (New York, USA)

  • EPIDEMIOLOGICAL OVERVIEW OF PARKINSON’S DISEASE IN BRAZIL

    S. Moura, R. Oliveira, L. Cruz, N. Cruz, A. Moura, N. Oliveira (Salvador, Brazil)

  • Epidemiology of Huntington Disease in Tatarstan republic, Russia. One-moment investigation

    Z. Zalyalova, S. Munasipova, D. Khasanova (Kazan, Russian Federation)

  • Essential tremor versus essential tremor-plus: Response to ventralis intermedius nucleus deep brain stimulation

    G. Gilmour, D. Martino, K. Hunka, P. Lawrence, Z. Kiss, V. Bruno (Calgary, Canada)

  • Ethnic and Gender Disparities in Access to Deep Brain Stimulation Surgery for Movement Disorders in a Canadian Center

    S. Poonja, K. Yen, J. Miyasaki, A. Shetty, T. Sankar, F. Ba (Edmonton, Canada)

  • Evaluating a Novel Home-Based Care Pathway for People with Parkinson’s Disease

    E. King, J. Abraham, E. Edwards, T. Gorst, M. Holley, J. Inches, T. North, J. Rideout, S. Whipps, C. Carroll (Plymouth, United Kingdom)

  • Evaluating Engagement of ABBV-0805, an Anti-Alpha-Synuclein Monoclonal Antibody to Physiological and Pathological Forms of Alpha-Synuclein for Phase 2 Dose Selection: A PBPK Modeling and Simulation Approach

    H. Kalluri, S. Bhatnagar, L. Rueter, C. Zadikoff, O. Graff, P. Noertersheuser, H. Xiong (North Chicago, USA)

  • Evaluating palliative care needs in patients with Parkinson’s disease and related disorders

    K. Kay, A. Killoran (Iowa City, USA)

  • Evaluating Patients’ Preferences for Parkinson’s Disease Treatments

    M. Serbin, J. Sutphin, C. Leach, C. Mansfield, C. Yonan, O. Klepitskaya, M. Sheehan, A. Donnelly (San Diego, USA)

  • Evaluating the Relationship between Apathy and Grit as it Relates to Participation in a Community Exercise Program in the Population with Parkinson’s Disease.

    E. Kiernan (Gainesville, USA)

  • Evaluating the use of digital biomarkers to test treatment effects on cognition and motor in patients with Lewy Body Dementia

    J. Wang, C. Battioui, A. Mccarthy, X. Dang, H. Zhang, A. Man, J. Kyle, L. Munsie, M. Pugh, K. Biglan (Indianapolis, USA)

  • Evaluation of a double-target therapeutic in preclinical models of Parkinson’s disease

    FJ. Sanz, C. Solana-Manrique, E. Masià, MJ. Vicent, N. Paricio (Burjassot, Spain)

  • Evaluation of abnormal cerebellar iron distribution in idiopathic cervical dystonia using quantitative susceptibility mapping

    HX. Li, M. Zhang, YH. Wu, YF. Li, HJ. Wei, YW. Wu (Shanghai, China)

  • Evaluation of Acoustic Features of Speech for Monitoring Parkinson’s Disease Progression

    M. Magee, J. Tamplin, M. Morris, C. Marigliani, F. Baker, A. Tsanas, G. Noffs, A. Vogel (Parkville, Australia)

  • Evaluation of bedside tests of attention in delirium superimposed on Parkinson’s disease and dementia

    R. Lawson, S. Richardson, D. Kershaw, D. Davis, B. Stephan, L. Robinson, C. Brayne, L. Barnes, D. Burn, A. Yarnall, JP. Taylor, S. Parker, L. Allan (Newcastle Upon Tyne, United Kingdom)

  • Evaluation of Care delivery model for integrated care and self-management for people with Parkinson’s disease with Deep Brain Stimulation

    D. Dash, D. Cote, J. Conway, A. Basndwah, D. Grimes, T. Mestre (Ottawa, Canada)

  • Evaluation of cognitive function in patients with Essential Tremor in Mexican population

    A. Abundes-Corona, M. Rodríguez-Violante, A. Cervantes-Arriaga, H. Estrada-Rodriguez, L. Gaibor-Noboa, D. Vazquez-Guevara (Mexico City, Mexico)

  • Evaluation of CSF Assay usability for Huntington’s Disease (HD) Clinical Studies (mHTT, tHTT and NFL in HDClarity)

    D. Langbehn, D. Macdonald, C. Sampaio, A G. Ehrhardt (Iowa City, USA)

  • Evaluation of Health-Related Quality of Life for Individuals with Huntington’s Disease and Care Partners in Canada

    N. Budd, T. Mestre, E. Shaw, M. Mayer, P. Ekwaru, S. Mcmullen, E. Graves, J. Wu, B. Maturi, T. Cowling (Mississauga, Canada)

  • Evaluation of Motor Function Using Motor Testing App and Deep Learning for the Treatment of Lewy Body Dementia

    X. Dang, Y. Guan, K. Deng, J. Wang, H. Zhang, C. Battioui, M. Pugh, B. Winger, J. Yang, K. Biglan (Cambridge, USA)

  • EVALUATION OF MOTOR SPEECH DISORDERS IN PATIENTS WITH PARKINSON’S DISEASES.

    J. Santos, M. Olchik, R. Rech, I. Klein, A. Bertodo (Porto Alegre, Brazil)

  • EVALUATION OF THE ABSENCE OF NIGROSOME 1 BY MAGNETIC RESONANCE 3 TESLA IN PARKINSON’S DISEASE ACCORDING TO TIME OF EVOLUTION TO DIAGNOSIS VS MESENCEPHALIC ECOGRAPHY.

    J. Bestoso, L. Ciancaglini, C. Stefani, F. Silveira, M. Pérez Akly, J. Norscini, J. Funes, C. Besada, D. Bauso (Buenos Aires, Argentina)

  • Evaluation of the QTc prolongation risk of deutetrabenazine

    F. Schneider, B. Darpo, M. Gutierrez, M. Gordon, L. Rabinovich-Guilatt (Ulm, Germany)

  • Event-related oscillations in patients with Dementia with Lewy Bodies with and without mutations in the GBA gene

    Y. Rosenblum, N. Bregman, A. Thaler, A. Orr-Urtreger, N. Giladi, A. Mirelman, T. Shiner (Tel Aviv, Israel)

  • Evidence of gut dysbiosis in treatment-naïve de novo Parkinson’s disease

    J. Boertien, K. Murtomäki, P. Pereira, S. Vander Zee, A. Slomp, T. Mertsalmi, R. Levo, T. Nojonen, P. Laine, L. Paulin, P. Auvinen, V. Kaasinen, F. Scheperjans, T. van Laar (Groningen, Netherlands)

  • Evidence of Overlapping Pathology between Depression and Autonomic Dysfunction in Parkinson’s Disease

    M. Sklerov, E. Dayan, N. Browner, D. Rubinow, F. Frohlich (Chapel Hill, USA)

  • Evoked potentials as biomarker for deep brain stimulation programming in Parkinson’s disease

    J. Peeters, A. Boogers, T. van Bogaert, R. Gransier, J. Wouters, B. Nuttin, M. Mc Laughlin (Leuven, Belgium)

  • Evolution of disability in spinocerebellar ataxias type 1, 2, 3, and 6

    H. Jacobi, T. Schaprian, J. Beyersmann, S. Tezenas, T. Klockgether (Heidelberg, Germany)

  • EVOLUTION OF PARKINSON’S DISEASE IN PATIENTS WITH ESSENTIAL TREMOR: CLINICAL AND NEUROIMAGING ASPECTS

    G. Froehner, C. Camargo, G. Fabiani, A. Meira, H. Teive (Curitiba, Brazil)

  • Evolving inclusion criteria in early manifest Huntington’s disease (HD) to address striatal atrophy: Lessons from HD-GeneTRX-1, the first gene therapy trial

    E. Furr-Stimming, C. Testa, P. Larson, C. Ross, R. Lonser, A. Samii, D. Cooper, S. Ying, M. Clarkin, E. Sawyer, R. Reilmann (Houston, USA)

  • Excessive directional antisaccade errors in Tourette Syndrome with Attention-deficit Hyperactivity Disorder: a case report

    DSL. Sandoval-Lopez, JOM. Ortega-Márquez, DPP. Pérez-Plascencia, DCJ. Chapa-Juárez, COA. Ortéga-Arenas, AAS. Armas-Salazar (Mexico City, Mexico)

  • Exercise habits of People with Parkinson’s across different ethnic populations

    A. Podlewska, A. Sauerbier, D. van Wamelen, L. Batzu, V. Leta, I. Subramanian, K. Ray Chaudhuri (London, United Kingdom)

  • Expanding the phenotypic spectrum of diabetic striatopathy: a case series

    N. Chunga, G. Schifitto, R. Ramchandran, A. Lang, K. Lizarraga (Rochester, USA)

  • Experience of DBS programming with directional leads

    J. Karl, J. Joyce, L. Verhagen Metman (Chicago, USA)

  • Experiences of home-based dance participation in people with Parkinson’s

    J. Bek, M. Groves, D. Leventhal, E. Poliakoff (Manchester, United Kingdom)

  • Exploring Local Field Potential changes in Dystonic Camptocormia.

    M. Chua, C. Harrington, S. Stanslaski, M. Hayes, G. Cosgrove, T. Herrington (Boston, USA)

  • Exploring the Potential Anti-dementia Roles of Selected Herbal Anti-inflammatory Remedies in Parkinson’s Disease: Hopes and Challenges

    SA. Atunwa (Ilorin, Nigeria)

  • Exploring the usefulness of Repetitive Transcranial Magnetic Stimulation for treatment of pain and fatigue in Parkinson’s disease

    A. Latorre, L. Rocchi, N. Manzo, J. Rothwell, K. Bhatia (London, United Kingdom)

  • Explosive onset of tic-like movements during the COVID pandemic among patients with no previous diagnosis of tic disorders

    C. Olvera, A. Kompoliti (Chicago, USA)

  • Extending the spectrum of non-motor symptoms in pre-motor Huntington’s disease – a pilot study

    B. Heim, D. Valent, F. Carbone, S. Spielberger, F. Krismer, A. Djamshidian, K. Seppi (Innsbruck, Austria)

  • Extensive volume increases sensitivity of alpha-synuclein accumulation in the gastrointestinal tract

    C. Shin, SI. Kim, SH. Park, HJ. Kim, B. Jeon (Sejong-Si, Republic of Korea)

  • EXTERNAL VALIDATION OF TWO PREDICTIVE TOOLS TO IDENTIFY PEOPLE WITH PARKINSON’S DISEASE AT RISK OF RECURRENT FALLS

    H. Cavalcanti, I. Rosa, M. Piemonte, A. Costa, G. Valença, J. Oliveira-Filho, L. Almeida (Cachoeira, Brazil)

  • Extracerebellar Signs and Symptoms in 117 Korean Patients with Early-Stage Spinocerebellar Ataxia

    M. Kim, JH. Ahn, JK. Mun, EH. Choi, JS. Kim, J. Youn, JW. Cho (Jinju, Republic of Korea)

  • extrapyramidal involvement in Horizontal gaze palsy with progressive scoliosis (HGPPS).

    M. Heidari, T. Khoeini, Z. Mirzaasgari, M. Almasi (Tehran, Islamic Republic of Iran)

  • Eye movement disorders in adolescents and adults with an inborn errors of metabolism

    L. Koens, T. de Koning, M. Tijssen (Groningen, Netherlands)

  • Eyelid opening apraxia as the first manifestation of Creutzfeldt- Jakob disease with 99mTc-TRODAT-1 brain SPECT study

    G. Fabiani, R. Filho, E. Hummelgen (Cg Sul, Brazil)

Jump to:  View All • a b c d [e] f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley